<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162550</url>
  </required_header>
  <id_info>
    <org_study_id>1026</org_study_id>
    <nct_id>NCT02162550</nct_id>
  </id_info>
  <brief_title>Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phoenix VA Health Care System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will be determining whether a once weekly injectable medication Bydureon versus
      placebo is able to reduce the development of atherosclerosis.

      Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will
      improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis
      plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies
      will provide novel information about the temporal relationship between Bydureon induced
      changes in risk factors, endothelial function and atherosclerosis progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      148 typical T2DM patients (ages 21-75) will participate in a rolling recruitment over
      approximately 2.25 years and be randomly allocated for 18 months to Bydureon (2 mg/week) or
      matching placebo subcutaneous injections 1x/week in a 2:1 ratio. Participants are expected to
      have a wide range of cardiovascular (CVD) risk and will therefore allow us to explore the
      importance of disease extent at baseline as a predictor of response. Blocked randomization
      will be used to ensure equal distribution of gender and CVD history. Carotid plaque MRI
      assessments will be performed at baseline, 9 and 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in carotid plaque volume</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the difference in change in carotid plaque volume, using 3 tesla (3T) MRI, between T2DM patients treated with Bydureon or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in reactive hyperemic index</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the effects of long-term Bydureon therapy on vascular function as measured by the difference in fasting and post prandial reactive hyperemic index using peripheral artery tonometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in carotid plaque composition</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the difference in change in carotid plaque composition, using 3 tesla (3T) MRI, between T2DM patients treated with Bydureon or placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Bydureon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injectable medication Bydureon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a similar looking injectable</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bydureon</intervention_name>
    <description>once weekly injection</description>
    <arm_group_label>Bydureon</arm_group_label>
    <other_name>long-acting exenatide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>once weekly injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive agent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on
             diet only

          -  take stable doses of oral antihyperglycemic agents with or without long-acting insulin

          -  must have a regular primary care provider (PCP) that is amenable to patient study
             participation and will facilitate (blinded to the treatment) the research team's study
             protocol efforts

        Exclusion Criteria:

          -  type 1 diabetes mellitus (T1DM)

          -  current or recent glucagon-like peptide 1 receptor (GLP-1R) agonist use

          -  contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus
             inappropriate for MRI exam)

          -  screening carotid ultrasound plaque thickness of &lt;0.75 mm, prior or anticipated
             carotid stenting or endarterectomy

          -  recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g.,
             pancreatitis, severe renal disease) or personal or family history of medullary thyroid
             carcinoma

          -  patients with Multiple Endocrine Neoplasia syndrome type 2

          -  serious hypersensitivity to exenatide or any product components

          -  severe gastrointestinal disease, or pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter D Reaven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carl T. Hayden Medical Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rubin Ramos</last_name>
    <phone>602-277-5551</phone>
    <phone_ext>5812</phone_ext>
    <email>Rubin.Ramos@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda McDonald, RN</last_name>
    <phone>602-277-5551</phone>
    <phone_ext>7063</phone_ext>
    <email>Linda.McDonald@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix VA Health Care System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter D. Reaven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Phoenix VA Health Care System</investigator_affiliation>
    <investigator_full_name>Peter Reaven</investigator_full_name>
    <investigator_title>Director, Diabetes Program</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Carotid Plaque</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Incretins</keyword>
  <keyword>Atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Subject to VA regulation.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

